Latest Targeted Therapies in Hormone Receptor Positive, Her2 Neu Negative Breast Carcinoma – A Review Article

Syed Ali Amir Sherazi
Additional contact information
Syed Ali Amir Sherazi: Jinnah Hospital, Lahore, Pakistan

Novel Approaches in Drug Designing & Development, 2018, vol. 4, issue 1, 15-19

Abstract: HelBreast cancer is the most frequently diagnosed cancer worldwide, accounting for over a million cases each year. It is also the leading cause of death in women worldwide. According to National Centre for health statistics, 17.3 million new cancer cases and 0.60 million deaths are projected to occur in United States in 2018 due to breast cancer [1]. Breast cancer is treated with a multidisciplinary approach involving surgical oncology, radiation oncology, and medical oncology, which has been associated with a reduction in breast cancer mortality [2].

Keywords: juniper publishers; drug designing pdf; drug designing articles; drug designing abstract; drug designing journal; modern approaches in drug designing journal; drug designing & intellectual properties international journal; peer reviewed open access journals; high impact journals; juniper publishers review (search for similar items in EconPapers)
Date: 2018
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://juniperpublishers.com/napdd/pdf/NAPDD.MS.ID.555630.pdf (application/pdf)
https://juniperpublishers.com/napdd/NAPDD.MS.ID.555630.php (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:adp:jnapdd:v:4:y:2018:i:1:p:15-19

DOI: 10.19080/NAPDD.2018.04.555630

Access Statistics for this article

Novel Approaches in Drug Designing & Development is currently edited by Sophia Mathis

More articles in Novel Approaches in Drug Designing & Development from Juniper Publishers Inc.
Bibliographic data for series maintained by Robert Thomas ().